SRR5088827
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.400
- GLYCOLYSIS+0.400
- HYPOXIA+0.400
- MYC_TARGETS_V1+0.400
- TGF_BETA_SIGNALING+0.400
- UNFOLDED_PROTEIN_RESPONSE+0.400
- DNA_REPAIR+0.300
- MTORC1_SIGNALING+0.300
- TNFA_SIGNALING_VIA_NFKB+0.300
- ANGIOGENESIS+0.200
Top 10 suppressed
- ALLOGRAFT_REJECTION-0.300
- BILE_ACID_METABOLISM-0.300
- INTERFERON_ALPHA_RESPONSE-0.300
- INTERFERON_GAMMA_RESPONSE-0.300
- MITOTIC_SPINDLE-0.300
- APICAL_SURFACE-0.200
- ESTROGEN_RESPONSE_EARLY-0.200
- FATTY_ACID_METABOLISM-0.200
- G2M_CHECKPOINT-0.200
- IL6_JAK_STAT3_SIGNALING-0.200
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-P3-A6T3-01A-11R-A34R-07 | — | — | 0.771 |
| 2 | SRR10842375 | — | — | 0.764 |
| 3 | BS_KP735TJ6 | high-grade glioma | — | 0.752 |
| 4 | ERR2278862 | — | — | 0.721 |
| 5 | eaecaea1-2cb7-472c-b549-ff779e5e1d30 | — | — | 0.683 |
| 6 | SRR2932813 | — | — | 0.675 |
| 7 | 350f38a2-e597-494a-a387-975814453726 | — | — | 0.673 |
| 8 | CBE04BB7-A357-484D-BFDB-2CAEEC629123 | — | — | 0.662 |
| 9 | TCGA-22-5482-01A-01R-1635-07 | — | cohortSQ2 | 0.661 |
| 10 | TCGA-CV-6945-01A-11R-1915-07 | — | — | 0.656 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 20 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.400 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.400 | Inavolisib | — uncovered |
| HYPOXIA | 0.400 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.400 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.400 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.400 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.300 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.300 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.300 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.200 | Remibrutinib | — uncovered |
| MYC_TARGETS_V2 | 0.200 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.200 | Remibrutinib | — uncovered |
| P53_PATHWAY | 0.200 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.200 | Remibrutinib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.200 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.100 | Inavolisib | — uncovered |
| APOPTOSIS | 0.100 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.100 | Remibrutinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.100 | Cobimetinib | — uncovered |
| UV_RESPONSE_UP | 0.100 | Idelalisib | — uncovered |